Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Cannabis Bioscience International Holdings (CBIH) EBT Margin (2022 - 2025)

Cannabis Bioscience International Holdings' EBT Margin history spans 3 years, with the latest figure at 213.53% for Q4 2025.

  • For Q4 2025, EBT Margin fell 11813.0% year-over-year to 213.53%; the TTM value through Nov 2025 reached 358.44%, down 21251.0%, while the annual FY2025 figure was 139.05%, 11828.0% up from the prior year.
  • EBT Margin for Q4 2025 was 213.53% at Cannabis Bioscience International Holdings, up from 380.79% in the prior quarter.
  • Across five years, EBT Margin topped out at 55.87% in Q3 2024 and bottomed at 999.32% in Q1 2025.
  • The 3-year median for EBT Margin is 269.84% (2025), against an average of 370.63%.
  • The largest annual shift saw EBT Margin soared 43022bps in 2024 before it tumbled -34690bps in 2025.
  • A 3-year view of EBT Margin shows it stood at 195.19% in 2023, then skyrocketed by 51bps to 95.39% in 2024, then tumbled by -124bps to 213.53% in 2025.
  • Per Business Quant, the three most recent readings for CBIH's EBT Margin are 213.53% (Q4 2025), 380.79% (Q3 2025), and 290.04% (Q2 2025).